Form 4: Director Zhao Baiteng Receives Whitehawk Stock Options
Statement of Changes in Beneficial Ownership
Director Zhao Baiteng was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.
Summary
- Director Zhao Baiteng received a grant of 38,040 stock options on June 12, 2026.
- The options have an exercise price of $4.16 per share.
- The options are set to expire on June 12, 2036.
- Vesting is contingent upon the director remaining a service provider through the earlier of the one-year anniversary of the grant or the day before the next annual stockholders meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- Vesting is subject to continued service, creating a dependency on the director's ongoing relationship with the company.
Future Outlook
The options vest fully on the earlier of the one-year anniversary of the grant or the day prior to the next annual meeting of stockholders, provided the director remains a service provider.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The grant of stock options as part of director compensation is consistent with standard practices for small-cap biotechnology firms.
- The ten-year expiration term is a standard duration for executive and director equity incentive plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 38,040 stock options to Director Zhao Baiteng under the 2021 Equity Incentive Plan. | 06/12/2026 | Increases director's equity stake, aligning incentives with shareholders. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options on the earlier of June 12, 2027, or the day before the next annual stockholders meeting.
Key Dates
| Date | Description |
|---|---|
| 06/12/2026 | Date of grant for stock options and earliest transaction date. |
| 06/12/2036 | Expiration date of the granted stock options. |
Keywords
Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.